Literature DB >> 29941650

Combination of Amino Acid Substitutions Leading to CTX-M-15-Mediated Resistance to the Ceftazidime-Avibactam Combination.

Fabrice Compain1,2, Delphine Dorchène1, Michel Arthur3.   

Abstract

Single amino acid substitutions in the Ω loop of KPC β-lactamases are known to lead to resistance to the ceftazidime-avibactam combination. Here, we investigate this mechanism of resistance in CTX-M enzymes, which are the most widely spread extended-spectrum β-lactamases worldwide. Nine single amino acid polymorphisms were identified in the Ω loop of the 172 CTX-M sequences present in the Lahey database of β-lactamases. The corresponding modifications were introduced in CTX-M-15 by site-directed mutagenesis. None of the nine substitutions was associated with ceftazidime-avibactam resistance in Escherichia coli TOP10. However, two substitutions led to 4-fold (P167S) and 16-fold (L169Q) increases in the MIC of ceftazidime. We determined whether these substitutions favor the in vitro selection of mutants resistant to ceftazidime-avibactam. The selection provided mutants for the L169Q substitution but not for the P167S substitution or for the parental enzyme CTX-M-15. Resistance to the drug combination (MIC of ceftazidime, 16 μg/ml in the presence of 4 μg/ml of avibactam) resulted from the acquisition of the S130G substitution by CTX-M-15 L169Q. Purified CTX-M-15 with the two substitutions, L169Q and S130G, was only partially inhibited by avibactam at concentrations as high as 50,000 μM but retained ceftazidime hydrolysis activity with partially compensatory decreases in kcat and Km These results indicate that emergence of resistance to the ceftazidime-avibactam combination requires more than one mutation in most CTX-M-encoding genes. Acquisition of resistance could be restricted to rare variants harboring predisposing polymorphisms such as Q at position 169 detected in a single naturally occurring CTX-M enzyme (CTX-M-93).
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  CTX-M; avibactam; ceftazidime; Ω loop; β-lactamase inhibitor

Mesh:

Substances:

Year:  2018        PMID: 29941650      PMCID: PMC6125495          DOI: 10.1128/AAC.00357-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.

Authors:  Krisztina M Papp-Wallace; Marisa L Winkler; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

2.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

3.  Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis.

Authors:  Peter S Levitt; Krisztina M Papp-Wallace; Magdalena A Taracila; Andrea M Hujer; Marisa L Winkler; Kerri M Smith; Yan Xu; Michael E Harris; Robert A Bonomo
Journal:  J Biol Chem       Date:  2012-07-26       Impact factor: 5.157

4.  Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.

Authors:  Hervé Dupont; Olivier Gaillot; Anne-Sophie Goetgheluck; Claire Plassart; Jean-Philippe Emond; Marion Lecuru; Nicolas Gaillard; Sarah Derdouri; Baptiste Lemaire; Marion Girard de Courtilles; Vincent Cattoir; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

5.  CTX-M-93, a CTX-M variant lacking penicillin hydrolytic activity.

Authors:  Laura Djamdjian; Thierry Naas; Didier Tandé; Gaelle Cuzon; Catherine Hanrotel-Saliou; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

6.  Evolution of antibiotic resistance: several different amino acid substitutions in an active site loop alter the substrate profile of beta-lactamase.

Authors:  T Palzkill; Q Q Le; K V Venkatachalam; M LaRocco; H Ocera
Journal:  Mol Microbiol       Date:  1994-04       Impact factor: 3.501

Review 7.  Multidrug-resistant Gram-negative bacteria: a product of globalization.

Authors:  P M Hawkey
Journal:  J Hosp Infect       Date:  2015-02-04       Impact factor: 3.926

8.  CTX-M-type extended-spectrum beta-lactamase that hydrolyzes ceftazidime through a single amino acid substitution in the omega loop.

Authors:  L Poirel; T Naas; I Le Thomas; A Karim; E Bingen; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

Review 10.  CTX-M-type β-lactamases: a successful story of antibiotic resistance.

Authors:  Marco Maria D'Andrea; Fabio Arena; Lucia Pallecchi; Gian Maria Rossolini
Journal:  Int J Med Microbiol       Date:  2013-03-13       Impact factor: 3.473

View more
  8 in total

Review 1.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 2.  Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations.

Authors:  Stephanie Ho; Lynn Nguyen; Trang Trinh; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2019-09-09       Impact factor: 3.725

3.  Ceftazidime-Avibactam Resistance Mediated by the N346Y Substitution in Various AmpC β-Lactamases.

Authors:  Fabrice Compain; Agathe Debray; Pauline Adjadj; Delphine Dorchêne; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

4.  Modulation of the Specificity of Carbapenems and Diazabicyclooctanes for Selective Activity against Mycobacterium tuberculosis.

Authors:  Jean-Philippe Barnier; Saidbakhrom Saidjalolov; Flavie Bouchet; Louis Mayer; Zainab Edoo; Inès Sayah; Laura Iannazzo; Mélanie Ethève-Quelquejeu; Jean-Luc Mainardi; Emmanuelle Braud; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2022-08-09       Impact factor: 5.938

5.  Evolutionary Trajectories toward High-Level β-Lactam/β-Lactamase Inhibitor Resistance in the Presence of Multiple β-Lactamases.

Authors:  Fredrika Rajer; Lisa Allander; Philip A Karlsson; Linus Sandegren
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

Review 6.  Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.

Authors:  Paolo Gaibani; Tommaso Giani; Federica Bovo; Donatella Lombardo; Stefano Amadesi; Tiziana Lazzarotto; Marco Coppi; Gian Maria Rossolini; Simone Ambretti
Journal:  Antibiotics (Basel)       Date:  2022-05-06

7.  KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.

Authors:  Agnès B Jousset; Saoussen Oueslati; Cécile Emeraud; Rémy A Bonnin; Laurent Dortet; Bogdan I Iorga; Thierry Naas
Journal:  Antimicrob Agents Chemother       Date:  2021-10-04       Impact factor: 5.191

Review 8.  New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.

Authors:  Juan C Vázquez-Ucha; Jorge Arca-Suárez; Germán Bou; Alejandro Beceiro
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.